The cholesterol-lowering therapy evolocumab reduced the risk of major adverse cardiac events by nearly one-third among patients who had no known significant atherosclerosis and had diabetes, according to a study presented at the American College of Cardiology’s Annual Scientific Session.
To continue reading click here
